XPRESIDENT® is a powerful target discovery engine that identifies TUMAPs directly from primary tumor tissue by a combination of genomics, mass spectrometry, bioinformatics and T-cell immunology. Immatics is building a rapidly growing and strong pipeline of oncology drug candidates based on the most efficient target discovery engine presently available to the pharmaceutical industry.
Adoptive Cell Therapy, TCR and Ab bispecifics
Driven by both Immatics’ XPRESIDENT® target discovery platform and MD Anderson Cancer Center’s significant expertise in Adoptive Cell Therapy (ACT), work is focused on the development of three ACT approaches to treat cancer: ACTolog®, ACTengine® and ACTallo®. Learn more about these approaches here.
Immatics is engaged in the development of T-cell receptors (TCR) and antibody (Ab) bispecifics, both targeting XPRESIDENT® discovered TUMAPs.
In 2013 Roche and Immatics have committed to develop and commercialize a number of new cancer peptide antigen-based immunotherapies, targeting primarily gastric, prostate and non-small cell lung cancer.
In 2015 Immatics and MorphoSys initiated a strategic alliance to develop Ab-based therapies targeting TUMAPs.
Beginning January 2017 Amgen and Immatics will develop and commercialize novel TCR- and Ab-based bispecific cancer drugs.